I agree Pharma, I was pleasantly surprised. Evolis and Jo-Ju are really kicking goals. They have seemed to put a lot more attention to detail with sales by region and all the relevant parties involved (except for Midkine). Maybe though, my expectations are too low.....
This statement also brings in a lot of promise for Lyramid:
As companies in Europe and in the UK started to return to their offices and their laboratories from 1 July 2020, we anticipate progress in some of the ongoing negotiations in the coming months.
- Forums
- ASX - By Stock
- Ann: Appendix 4C and Quarterly Activity Report
I agree Pharma, I was pleasantly surprised. Evolis and Jo-Ju are...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable